



Transcatheter Closure of ASD: Does Age Matter?

세브란스병원 SEVERANCE HOST

Jae Young Choi Severance Cardiovascular Hospital, Yonsei University Health System Seoul, Korea





- Introduction -

- Transcatheter closure of secundum ASD has been accepted as an attractive option of standard Tx.
- There may be a substantial resistance against a clinical decision for device closure in either very young or old patients,

probably because of the paucity of data and/or lacking of individual experience in this extreme age group of patients.

→ Is device closure safe and effective in very young or very old patients?

ASD closure in small children

- Optimal timing of known ASD closure: 1~5yrs
- The need for early intervention in small children
 - ; special clinical setting for an early closure;
 - Chronic lung disease in premature infants
 - Chr'some anomaly with compromised CPF
 - Recurrent resp. problem +/- airway anomaly
 - ; secundun ASD may "outgrow"
 - → "suitable" ASD for device closure may be changed to an "unsuitable" ASD

McMahon et al. Heart 2002, Tortoriello et al. Pedatr Cardiol 2002, Holzer R and Hijazi ZM. Curr Opin Cardiol 2004

→ Timing of treatment in the era of device closure : How small is too small? & How early is too early?

ANGIOPLASTY SUMM





What's been revealed so far? - Surgery-

Surgical ASD closure in young children

- 1996 J Card Surgery, Mainwairung RD et al
 5 of 6 infants; little or no benefit in symptom
- but contradictory results reported by
- 1981 Arch Dis Child, Bull C et al.
 - \rightarrow some of the infants c ASD requires early surgery
- 2004 Asian Cardiovasc Thorac Ann, Parvathy U et al.
 → 18pts < 2yrs; early surgery in symptomatic pts
- 2005 JTCS, Lammers A et al. 24 symptomatic infants
 - → early surgery should be performed in symptomatic infants with compromised lungs





What's been revealed so far?

- Device Closure -

Recent literatures for transcatheter ASD closure in young children

- 2003 JACC, Butera et al : 48pts < 5yrs

- \rightarrow 100% closure without complication, Sx relieved
- 2007 CCI, Cardenas et al. : 52pts < 15kg, 70% symptomatic infants
 → device closure is a safe and effective alternative
- 2007 JTCS, Diab et al : 15 infants, 11 percutaneous, 3 peratrial (3.0~8.3kg, median 5.6kg, mean<5.5kg)
 → device closure is a safe and effective alternative

- 2008 PICS, Choi et al : 24 device vs 16 surgery < 10kg

→ device closure is a safe and effective alternative, The advantage over surgery is valid in small children

- 2011 CHD, Wood et al : 9 ASD infants c BPD (+ 6 other LR shunt dis.)
 → device closure is a safe and effective


Problems encountered during the device device


- Large delivery system / small vascular access
 - → damage to vascular access
- Rigid coupling of device-delivery cable & relatively stiff delivery system
 - → damage to the cardiac structure
 - \rightarrow difficulty in checking the proper device position
- Excessive rim width of atrial discs in small devices
 - → device contact to adjacent structures, esp. mitral valve (potential abandonment of the procedure)
 - → small total septal length preclude implantation of a larger device
- Small LA : insufficient space for opening of the LA disc
- Lack of long-term data in small children



















LA disc encroaching to MV :

- often >5mm rim is not sufficient
- more common problem in small children !



Yonsei Pediatric Cardiology





Solutions for problems encountered during the device closure in small children


- Damage to vascular access & cardiac structure
 : sophisticated technique & meticulous approach are
 needed
- Excessive rim width of atrial discs in small devices
 - : need further device modification
 - : <u>"stopgap" technique</u>
 - choose a device acc. to the total septal length (=LA disc diameter) Amin Z. CCI 2006;68:778 Fischer G et al. CCI 2009;73:949
- Technical modifications such as BAT are also useful in small children Dalvi BV et al. CCI 2008;71:679



- ASD closure in the elderly -

- Ittle basis for survival benefit; lack of study in long-term base
- sufficient data for improvement of symptom, exercise tolerance, dysrhythmia & QOL, + reverse remodelling of heart

Pathophysiology







Literatures for surgical ASD closure in the elderly

- 1996 ATS, Shibata Y et al. : 49pts > 50yrs
 - → satisfactory long-term results, improves QOL: ASD repair in elderly pts without severe PVD should not be delayed
 - 1997 Jpn Heart J, Miyaji K et al. : comparing 40~69yrs vs >70yrs
 - → functional class & TR improved. to prevent progressive TV annular dilatation, surgical closure should be performed.
 - 2001 JACC, Attie F et al. : 521 pts > 40yrs, randomized study
 - → anatomic closure is superior to medical tx in preventing major event. Operation must be performed as soon as possible, even if symptom seems to be minimal.

pros - Konstantinides et al. (N Engl J Med, 1995), Steele et al. (Circulation, 1987) : nonrandomized cons - Shah et al. (Br Heart J, 1994) : nonrandomized

- 2001 Heart, Jemielity M et al. : 76 pts > 40yrs

→ improve clinical status / prevent RV dilation & insufficiency.





What's been revealed so far? - Device Closure -

Literatures for ASD device closure in the elderly (>60 yrs)

- 2005 CCI, Schubert s. et al. : 59pts > 60yrs, 25% LV restriction
 - → no complication in non-restrictive LV, pre-medication required in restrictive LV(25%), fenestrated device needed in 2pts(3.4%).
- 2006 IJC, Swan L et al : 50pts > 60yrs
 - → device closure is safe in elderly. Rt. heart shows remodeling. post-closure pulm edema in 1 pt. resolved by diuretics.
- 2009 Korean Circ J, Spies C et al : 55pts > 60yrs
 - → safe & effective; 100% success, no major complication. functional status improved, RV remodeling occurred.
 - 2009 CCI, Taniguchi M et al : 9pts > 60yrs with chr. A Fib
 - → improved functional class in all patients, geometric remodeling occurs.



Problems in device closure for the elderly

- More complex clinical presentation: frequent comorbid cardiac +/- systemic diseases
 - Atrial arrhythmia
 - LV diastolic failure and/or restriction (LV dysfunction after closure)
 - Pulmonary hypertension
 - Decompensated RV failure
 - Paradoxical embolism, etc






Incidence of Co-morbid Cardiac & Systemic Diseases among Elderly Patients > 60 yrs

	Schubert (2006) (Berlin, 59pts)	Swan (2005) (Toronto, 50pts)	Spies (2009) (Chcago, 55pts)
Systemic disease			
Hypertension (%)	42.4	34	?
DM (%)	?	6	?
Lung Disease (%)	?	4	?
Cerebral insult (%)	13.6	?	?
Cardiac comorbidity			
Pulm Hypertension (%)	49	?	42
A Fib +/- A Flutt (%)	40	20	24
Coronary HD (%)	13.6	16	?
LV dysfunction (%)	-	8	-
or LV restriction (%)	25	-	-
Pulm edema or (%) Fenestrated device (%	- %) 3.4	2	3.6







Risk factors of persistent or newlydeveloped atrial fibrillation / flutter



- Gatzoulis MA et al, N Engl J Med, 1999,

- Oliver JM et al. Am J Cardiol 2002,
- Silversides CK et al, Heart 2004





2009 Korean Circ J, Spies C et al





Patients c severe pulm. HiBP
 Elderly patients at high risk of post-procedural LV dysfunction



 \rightarrow Self-fabricated <u>fenestrated device</u>





Experience of Severance Cardiovascular Hospital

Subjects & Method

- 977 patients with ASD secundum
 - : 7-year period 2004. 04 ~ 2011. 03
 - Device closure : 754 pts

group 1 : 79 small childrenwt 10kg or lessgroup 2 : 627 patientswt>10kg & age<60yrs</td>group 3 : 48p elderly ptsage 60yrs or more

: comparison of hemodynamic & clinical parameters

- Surgical closure : 223 pts
 - : factors prevent device closure*
 - *: except for personal reasons; financial problem, etc





Demographic & Hemodynamic Data of Device Group

ASO group	Group 1 (n=79)	Group 2 (n=627)	Group 3 (n=48)	<i>P</i> -value
Age (year)	1.2±0.4	26.3±18.3	63.9±5.9	<0.001
Weight (kg)	9.1±1.1	46.3±11.4	60.8±9.8	<0.001, 0.002
Female (%)	57 (72%)	433 (69%)	38 (79%)	n/s
Qp/Qs	2.5±0.9	2.5±0.7	2.9±2.9	n/s
Defect size (mm)		23.0±7.5	25.0±6.0	<0.001
Device size (mm)	13.9±3.4	23.2±7.4	24.7±6.1	<0.001
Multiple defect (%)		100 (16%)	10 (21%)	0.015
PAP (mmHg)	27.1±6.2	31.7±11.3	37.7±10.1	0.035, 0.023, 0.001
PAH (%)		94 (15%)	19 (39%)	<0.001
Arrhythmia (%)	0 (0%)	19 (3%)	10 (21%)	<0.001

- Statistics; One-way ANOVA, Kruskal-Wallis test






Comparison of Immediate and F/U Results among Each Subgroups

ASO group	Group 1 (n=79)	Group 2 (n=627)	Group 3 (n=48)	<i>P</i> -value
PSR* (%)	79/82 (96%)	627/645 (97%)	48/48 (100%)	n/s
RSR** (%)	2 (2.6%)	6 (1%)	1 (2%)	n/s
Complication rate (%)	1# (1.3%)	12 ^{\$} (1.9%)	1 [†] (2.0%)	n/s
Procedure time (min)	67.8±19.6	65.1±17.9	66.8±16.8	n/s
Fluoroscopy time (min)			18.5±8.4	0.001

*: Procedural Success Rate, **: Residual Shunt Rate, #: 1 minimal pericardial effusion, \$: 4 minimal pericardial effusion, 3 groin hematoma, 2 transient neurologic abnormality, 3 transient arrhythmia, †: 1 atrial fibrillation



Interfering Factors Preventing from Device Closure in Surgery Group



Yonsei Pediatric Cardiology

ANGIOPLASTY SUMMIT

TCTAP 2012





Take Home Message (I) For small children,

- More sophisticated technical approach and decision is needed with regard to the fact that the closure system haven't specifically designed for small and fragile heart and vessel of very young children.
- Further modification of device toward decreased rim to waist diameter ratio is warranted to extend the applicability of this versatile treatment modality





Take Home Message (II)

For elderly patients,

- Thorough evaluation of co-morbidity and risk factors is important to predict post-procedural complication and to plan treatment strategy.
- The physician must let their patients know about serious complications such as chronic atrial arrhythmia and PAH which may persist after the ASD closure so that they can make right decision in choosing the treatment modality and promote compliance to further medical treatment.
- LV dysfunction (LV restriction) after device closure is rare, but potentially fatal outcome may be prevented by meticulous evaluation and appropriate treatment plan.





Conclusion

- Transcatheter closure of secundum ASD with ASO is technically feasible, safe and effective in a wide range of age.
 - Meticulous approach and individualized strategy for each patient are mandatory to maximize the efficacy and safety of this versatile therapy.